Combination therapy for the treatment of lower urinary tract symptoms in men

Q4 Medicine

Revista mexicana de urologia Pub Date : 2016-11-01 DOI:10.1016/j.uromx.2016.05.007

I. Barragán-Arteaga , L. Reyes-Vallejo

{"title":"Combination therapy for the treatment of lower urinary tract symptoms in men","authors":"I. Barragán-Arteaga , L. Reyes-Vallejo","doi":"10.1016/j.uromx.2016.05.007","DOIUrl":null,"url":null,"abstract":"<div><p>Recent interest in the coadministration of approved pharmaceutical agents has resulted in a wealth of emerging data on the safety and efficacy of dual pharmacological treatment for lower urinary tract symptoms (LUTS). Much evidence supports the coadministration of α-blockers with 5-alpha-reductase inhibitors (5-ARIs) in patients at risk for clinical progression. The use of phosphodiesterase-5 inhibitors (PDE5Is) in combination with 5-ARIs has also demonstrated a good safety and efficacy profile, providing early symptomatic relief and reduction of sexual side effects associated with 5-ARI use, although longer-term studies are needed. Studies investigating the combination of PDE5Is with α-blockers have shown additive effects on each of the individual agents with respect to the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF), which holds promise for patients who have shown a poor response to monotherapy. The coadministration of α-blockers and antimuscarinic agents provides an alternative for treatment of storage symptoms in patients who have failed to respond to monotherapy. This review aims to summarize and comment on available evidence regarding the safety and efficacy of combination treatment for LUTS.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2016.05.007","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408516300258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Recent interest in the coadministration of approved pharmaceutical agents has resulted in a wealth of emerging data on the safety and efficacy of dual pharmacological treatment for lower urinary tract symptoms (LUTS). Much evidence supports the coadministration of α-blockers with 5-alpha-reductase inhibitors (5-ARIs) in patients at risk for clinical progression. The use of phosphodiesterase-5 inhibitors (PDE5Is) in combination with 5-ARIs has also demonstrated a good safety and efficacy profile, providing early symptomatic relief and reduction of sexual side effects associated with 5-ARI use, although longer-term studies are needed. Studies investigating the combination of PDE5Is with α-blockers have shown additive effects on each of the individual agents with respect to the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF), which holds promise for patients who have shown a poor response to monotherapy. The coadministration of α-blockers and antimuscarinic agents provides an alternative for treatment of storage symptoms in patients who have failed to respond to monotherapy. This review aims to summarize and comment on available evidence regarding the safety and efficacy of combination treatment for LUTS.

查看原文本刊更多论文

联合疗法治疗男性下尿路症状

最近对批准的药物药物联合用药的兴趣导致了大量关于双重药物治疗下尿路症状(LUTS)的安全性和有效性的新数据。许多证据支持α-受体阻滞剂与5- α-还原酶抑制剂(5-ARIs)在有临床进展风险的患者中联合使用。磷酸二酯酶-5抑制剂(PDE5Is)与5-ARI联合使用也显示出良好的安全性和有效性，提供早期症状缓解和减少与5-ARI使用相关的性副作用，尽管需要更长期的研究。研究PDE5Is与α-阻滞剂联合使用的研究显示，在国际前列腺症状评分(IPSS)和国际勃起功能指数(IIEF)方面，每种单独药物都有累加效应，这对那些对单一治疗反应不佳的患者来说是有希望的。α-受体阻滞剂和抗毒蕈碱药物的联合使用为治疗对单一疗法无效的患者的储存症状提供了另一种治疗方法。这篇综述旨在总结和评论关于联合治疗LUTS的安全性和有效性的现有证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista mexicana de urologia Medicine-Urology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.